This report provides a comprehensive analysis of the global pet tumor screening service market, which focuses on early cancer risk assessment for companion animals through non-invasive biomarker detection. Driven by aging pet populations and increasing owner awareness of preventive healthcare, the market is poised for significant growth through 2032. The study evaluates key segments, including liquid biopsy, genomic testing, and AI-driven cytology, while examining the competitive landscape, regional dynamics, and the evolving roles of veterinary laboratories and clinics.

Market Overview

The global Pet Tumor Screening Service market is projected to grow from US$ 621 million in 2025 to US$ 1029 million in 2032, representing a compound annual growth rate (CAGR) of 7.5% from 2026 to 2032.

Service Definition and Description

Definition: Pet Tumor Screening Service refers to cancer risk assessment and early screening services designed for companion animals, such as dogs and cats.

Methodology: The service typically utilizes biological specimens—including blood, urine, cytology samples, or other materials—to detect various indicators such as:

• Tumor-related biomarkers
• Nucleosome signals
• Circulating cell-free DNA
• Genetic mutations
• Epigenetic features
• Abnormal cellular morphology

Clinical Utility: These services assist in assessing potential cancer risk and are commonly utilized for:

• Annual wellness checkups for senior pets
• Screening of high-risk breeds
• Adjunctive diagnosis for suspicious clinical signs
• Post-treatment recurrence monitoring

Note: While these services serve as an important front-end tool for early cancer detection and pet health management, they do not fully replace imaging, histopathology, or clinical diagnosis.

Pricing Structure:

• Basic Screening: Blood- or urine-based tests typically range from USD 100–300 per test.
• High-End Testing: Liquid biopsy, genomic, or epigenomic testing typically costs between USD 500–1,000 per test.

Supply Chain Analysis

Upstream

Includes the providers of essential components and tools:

• Antibodies, enzymes, primers, and probes
• Sequencing reagents
• Sample collection tubes and preservation solutions
• Diagnostic kits
• Testing instruments and automated analysis platforms
• AI pathology algorithms and bioinformatics systems
• Note: Core reagents and analytical models directly influence test sensitivity, specificity, and result interpretation.

Midstream

Participants responsible for assay development, sample processing, laboratory testing, report generation, and clinical interpretation:

• Veterinary diagnostic laboratories
• Pet molecular diagnostics companies
• Liquid biopsy developers
• Digital pathology platforms
• Large pet healthcare groups

Downstream

End-users and service delivery channels:

• Users: Veterinary hospitals, clinics, veterinary oncology centers, pet wellness providers, breeding institutions, and premium pet health management customers.
• Delivery Methods: Clinic-based sample submission, in-clinic testing, at-home sample collection, or integrated pet wellness packages.

Market Dynamics

Growth Drivers and Trends

The market is currently in an early growth stage, driven by the increasing sophistication and preventive orientation of pet healthcare. Key drivers include:

• Pet aging populations
• Rising owner awareness regarding proactive health management
• The growing burden of cancer in companion animals
• The upgrading of premium veterinary wellness packages

Competitive Advantages

Compared to traditional pathology and imaging diagnostics, these services offer:

• Early screening capabilities
• Non-invasive or minimally invasive sampling
• Repeatable monitoring
• Convenient delivery methods

Future Competitive Landscape

Future competition is expected to focus on:

• Test accuracy and clinical validation
• Veterinary channel coverage
• Report interpretability and price acceptance
• Integration with imaging, pathology, and treatment services
• Note: Companies possessing strong brand trust and extensive laboratory network advantages are positioned for scalable growth.

Report Scope and Methodology

This LPI (LP Information) research report, titled “Pet Tumor Screening Service Industry Forecast,” provides a comprehensive analysis of the global industry.

Key Report Features:

• Historical and Projected Data: Reviews total world sales in 2025 and provides projected sales analysis from 2026 through 2032.
• Granular Analysis: Detailed breakdown in US$ millions by region, market sector, and sub-sector.
• Strategic Insights: Analyzes global company strategies, including product portfolios, market entry tactics, market positions, and geographic footprints.
• Market Intelligence: Highlights trends in product segmentation, company formation, revenue, market share, latest developments, and M&A activity.
• Methodology: Employs a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs to provide a nuanced view of the market's trajectory.

Market Segmentation

By Type

• Blood Biomarker-Based Tumor Screening Services
• Liquid Biopsy and Genomic Testing Services
• Urine-Based or Volatile Metabolite Screening Services
• AI Cytology and Digital Pathology Screening Services

By Service Delivery Model

• Canine Virus Diagnostic Kits
• Feline Virus Diagnostic Kits
• Companion Animal Virus Diagnostic Kits

By Screening Purpose

• Single-Target Virus Test Kits
• Dual or Triple Combination Test Kits
• Multiplex Pathogen Panel Kits
• Instrument-Based Quantitative Kits

By Application

• Veterinary Hospitals and Clinics
• Veterinary Reference Laboratories
• Animal Shelters, Breeding and Rescue Centers
• Others

By Region

• Americas: United States, Canada, Mexico, Brazil
• APAC: China, Japan, Korea, Southeast Asia, India, Australia
• Europe: Germany, France, UK, Italy, Russia
• Middle East & Africa: Egypt, South Africa, Israel, Turkey, GCC Countries

Key Players

The following companies have been profiled based on primary expert input and analysis of their coverage, product portfolio, and market penetration:

• IDEXX Laboratories
• Zoetis Diagnostics
• Antech Diagnostics
• VolitionRx
• VDI Laboratory
• Oncotect
• CanCan Diagnostics
• Oxford BioDynamics
• FUJIFILM VET Systems
• Veterinary Pathology Group
• NationWide Laboratories
• BioGuard Corporation
• PETcision Biotech
• Uni-Pharma

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Pet Tumor Screening Service Market Size (2021-2032)

    • 2.1.2 Pet Tumor Screening Service Market Size CAGR by Region (2021 VS 2025 VS 2032)

    • 2.1.3 World Current & Future Analysis for Pet Tumor Screening Service by Country/Region (2021, 2025 & 2032)

  • 2.2 Pet Tumor Screening Service Segment by Type

    • 2.2.1 Blood Biomarker-Based Tumor Screening Services

    • 2.2.2 Liquid Biopsy and Genomic Testing Services

    • 2.2.3 Urine-Based or Volatile Metabolite Screening Services

    • 2.2.4 AI Cytology and Digital Pathology Screening Services

    • 2.2.5 Pet Tumor Screening Service Market Size by Type

      • 2.2.5.1 Pet Tumor Screening Service Market Size CAGR by Type (2021 VS 2025 VS 2032)
      • 2.2.5.2 Global Pet Tumor Screening Service Market Size Market Share by Type (2021-2026)

  • 2.3 Pet Tumor Screening Service Segment by Service Delivery Model

    • 2.3.1 Canine Virus Diagnostic Kits

    • 2.3.2 Feline Virus Diagnostic Kits

    • 2.3.3 Companion Animal Virus Diagnostic Kits

    • 2.3.4 Pet Tumor Screening Service Market Size by Service Delivery Model

      • 2.3.4.1 Pet Tumor Screening Service Market Size CAGR by Service Delivery Model (2021 VS 2025 VS 2032)
      • 2.3.4.2 Global Pet Tumor Screening Service Market Size Market Share by Service Delivery Model (2021-2026)

  • 2.4 Pet Tumor Screening Service Segment by Screening Purpose

    • 2.4.1 Single-Target Virus Test Kits

    • 2.4.2 Dual or Triple Combination Test Kits

    • 2.4.3 Multiplex Pathogen Panel Kits

    • 2.4.4 Instrument-Based Quantitative Kits

    • 2.4.5 Pet Tumor Screening Service Market Size by Screening Purpose

      • 2.4.5.1 Pet Tumor Screening Service Market Size CAGR by Screening Purpose (2021 VS 2025 VS 2032)
      • 2.4.5.2 Global Pet Tumor Screening Service Market Size Market Share by Screening Purpose (2021-2026)

  • 2.5 Pet Tumor Screening Service Segment by Application

    • 2.5.1 Veterinary Hospitals and Clinics

    • 2.5.2 Veterinary Reference Laboratories

    • 2.5.3 Animal Shelters, Breeding and Rescue Centers

    • 2.5.4 Others

    • 2.5.5 Pet Tumor Screening Service Market Size by Application

      • 2.5.5.1 Pet Tumor Screening Service Market Size CAGR by Application (2021 VS 2025 VS 2032)
      • 2.5.5.2 Global Pet Tumor Screening Service Market Size Market Share by Application (2021-2026)

• 3 Pet Tumor Screening Service Market Size by Player

  • 3.1 Pet Tumor Screening Service Market Size Market Share by Player

    • 3.1.1 Global Pet Tumor Screening Service Revenue by Player (2021-2026)

    • 3.1.2 Global Pet Tumor Screening Service Revenue Market Share by Player (2021-2026)

  • 3.2 Global Pet Tumor Screening Service Key Players Head office and Products Offered

  • 3.3 Market Concentration Rate Analysis

    • 3.3.1 Competition Landscape Analysis

    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.4 New Products and Potential Entrants

  • 3.5 Mergers & Acquisitions, Expansion

• 4 Pet Tumor Screening Service by Region

  • 4.1 Pet Tumor Screening Service Market Size by Region (2021-2026)

  • 4.2 Global Pet Tumor Screening Service Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Pet Tumor Screening Service Market Size Growth (2021-2026)

  • 4.4 APAC Pet Tumor Screening Service Market Size Growth (2021-2026)

  • 4.5 Europe Pet Tumor Screening Service Market Size Growth (2021-2026)

  • 4.6 Middle East & Africa Pet Tumor Screening Service Market Size Growth (2021-2026)

• 5 Americas

  • 5.1 Americas Pet Tumor Screening Service Market Size by Country (2021-2026)

  • 5.2 Americas Pet Tumor Screening Service Market Size by Type (2021-2026)

  • 5.3 Americas Pet Tumor Screening Service Market Size by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Pet Tumor Screening Service Market Size by Region (2021-2026)

  • 6.2 APAC Pet Tumor Screening Service Market Size by Type (2021-2026)

  • 6.3 APAC Pet Tumor Screening Service Market Size by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

• 7 Europe

  • 7.1 Europe Pet Tumor Screening Service Market Size by Country (2021-2026)

  • 7.2 Europe Pet Tumor Screening Service Market Size by Type (2021-2026)

  • 7.3 Europe Pet Tumor Screening Service Market Size by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Pet Tumor Screening Service by Region (2021-2026)

  • 8.2 Middle East & Africa Pet Tumor Screening Service Market Size by Type (2021-2026)

  • 8.3 Middle East & Africa Pet Tumor Screening Service Market Size by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Global Pet Tumor Screening Service Market Forecast

  • 10.1 Global Pet Tumor Screening Service Forecast by Region (2027-2032)

    • 10.1.1 Global Pet Tumor Screening Service Forecast by Region (2027-2032)

    • 10.1.2 Americas Pet Tumor Screening Service Forecast

    • 10.1.3 APAC Pet Tumor Screening Service Forecast

    • 10.1.4 Europe Pet Tumor Screening Service Forecast

    • 10.1.5 Middle East & Africa Pet Tumor Screening Service Forecast

  • 10.2 Americas Pet Tumor Screening Service Forecast by Country (2027-2032)

    • 10.2.1 United States Market Pet Tumor Screening Service Forecast

    • 10.2.2 Canada Market Pet Tumor Screening Service Forecast

    • 10.2.3 Mexico Market Pet Tumor Screening Service Forecast

    • 10.2.4 Brazil Market Pet Tumor Screening Service Forecast

  • 10.3 APAC Pet Tumor Screening Service Forecast by Region (2027-2032)

    • 10.3.1 China Pet Tumor Screening Service Market Forecast

    • 10.3.2 Japan Market Pet Tumor Screening Service Forecast

    • 10.3.3 Korea Market Pet Tumor Screening Service Forecast

    • 10.3.4 Southeast Asia Market Pet Tumor Screening Service Forecast

    • 10.3.5 India Market Pet Tumor Screening Service Forecast

    • 10.3.6 Australia Market Pet Tumor Screening Service Forecast

  • 10.4 Europe Pet Tumor Screening Service Forecast by Country (2027-2032)

    • 10.4.1 Germany Market Pet Tumor Screening Service Forecast

    • 10.4.2 France Market Pet Tumor Screening Service Forecast

    • 10.4.3 UK Market Pet Tumor Screening Service Forecast

    • 10.4.4 Italy Market Pet Tumor Screening Service Forecast

    • 10.4.5 Russia Market Pet Tumor Screening Service Forecast

  • 10.5 Middle East & Africa Pet Tumor Screening Service Forecast by Region (2027-2032)

    • 10.5.1 Egypt Market Pet Tumor Screening Service Forecast

    • 10.5.2 South Africa Market Pet Tumor Screening Service Forecast

    • 10.5.3 Israel Market Pet Tumor Screening Service Forecast

    • 10.5.4 Turkey Market Pet Tumor Screening Service Forecast

  • 10.6 Global Pet Tumor Screening Service Forecast by Type (2027-2032)

  • 10.7 Global Pet Tumor Screening Service Forecast by Application (2027-2032)

    • 10.7.1 GCC Countries Market Pet Tumor Screening Service Forecast

• 11 Key Players Analysis

  • 11.1 IDEXX Laboratories

    • 11.1.1 IDEXX Laboratories Company Information

    • 11.1.2 IDEXX Laboratories Pet Tumor Screening Service Product Offered

    • 11.1.3 IDEXX Laboratories Pet Tumor Screening Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.1.4 IDEXX Laboratories Main Business Overview

    • 11.1.5 IDEXX Laboratories Latest Developments

  • 11.2 Zoetis Diagnostics

    • 11.2.1 Zoetis Diagnostics Company Information

    • 11.2.2 Zoetis Diagnostics Pet Tumor Screening Service Product Offered

    • 11.2.3 Zoetis Diagnostics Pet Tumor Screening Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.2.4 Zoetis Diagnostics Main Business Overview

    • 11.2.5 Zoetis Diagnostics Latest Developments

  • 11.3 Antech Diagnostics

    • 11.3.1 Antech Diagnostics Company Information

    • 11.3.2 Antech Diagnostics Pet Tumor Screening Service Product Offered

    • 11.3.3 Antech Diagnostics Pet Tumor Screening Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.3.4 Antech Diagnostics Main Business Overview

    • 11.3.5 Antech Diagnostics Latest Developments

  • 11.4 VolitionRx

    • 11.4.1 VolitionRx Company Information

    • 11.4.2 VolitionRx Pet Tumor Screening Service Product Offered

    • 11.4.3 VolitionRx Pet Tumor Screening Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.4.4 VolitionRx Main Business Overview

    • 11.4.5 VolitionRx Latest Developments

  • 11.5 VDI Laboratory

    • 11.5.1 VDI Laboratory Company Information

    • 11.5.2 VDI Laboratory Pet Tumor Screening Service Product Offered

    • 11.5.3 VDI Laboratory Pet Tumor Screening Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.5.4 VDI Laboratory Main Business Overview

    • 11.5.5 VDI Laboratory Latest Developments

  • 11.6 Oncotect

    • 11.6.1 Oncotect Company Information

    • 11.6.2 Oncotect Pet Tumor Screening Service Product Offered

    • 11.6.3 Oncotect Pet Tumor Screening Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.6.4 Oncotect Main Business Overview

    • 11.6.5 Oncotect Latest Developments

  • 11.7 CanCan Diagnostics

    • 11.7.1 CanCan Diagnostics Company Information

    • 11.7.2 CanCan Diagnostics Pet Tumor Screening Service Product Offered

    • 11.7.3 CanCan Diagnostics Pet Tumor Screening Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.7.4 CanCan Diagnostics Main Business Overview

    • 11.7.5 CanCan Diagnostics Latest Developments

  • 11.8 Oxford BioDynamics

    • 11.8.1 Oxford BioDynamics Company Information

    • 11.8.2 Oxford BioDynamics Pet Tumor Screening Service Product Offered

    • 11.8.3 Oxford BioDynamics Pet Tumor Screening Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.8.4 Oxford BioDynamics Main Business Overview

    • 11.8.5 Oxford BioDynamics Latest Developments

  • 11.9 FUJIFILM VET Systems

    • 11.9.1 FUJIFILM VET Systems Company Information

    • 11.9.2 FUJIFILM VET Systems Pet Tumor Screening Service Product Offered

    • 11.9.3 FUJIFILM VET Systems Pet Tumor Screening Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.9.4 FUJIFILM VET Systems Main Business Overview

    • 11.9.5 FUJIFILM VET Systems Latest Developments

  • 11.10 Veterinary Pathology Group

    • 11.10.1 Veterinary Pathology Group Company Information

    • 11.10.2 Veterinary Pathology Group Pet Tumor Screening Service Product Offered

    • 11.10.3 Veterinary Pathology Group Pet Tumor Screening Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.10.4 Veterinary Pathology Group Main Business Overview

    • 11.10.5 Veterinary Pathology Group Latest Developments

  • 11.11 NationWide Laboratories

    • 11.11.1 NationWide Laboratories Company Information

    • 11.11.2 NationWide Laboratories Pet Tumor Screening Service Product Offered

    • 11.11.3 NationWide Laboratories Pet Tumor Screening Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.11.4 NationWide Laboratories Main Business Overview

    • 11.11.5 NationWide Laboratories Latest Developments

  • 11.12 BioGuard Corporation

    • 11.12.1 BioGuard Corporation Company Information

    • 11.12.2 BioGuard Corporation Pet Tumor Screening Service Product Offered

    • 11.12.3 BioGuard Corporation Pet Tumor Screening Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.12.4 BioGuard Corporation Main Business Overview

    • 11.12.5 BioGuard Corporation Latest Developments

  • 11.13 PETcision Biotech

    • 11.13.1 PETcision Biotech Company Information

    • 11.13.2 PETcision Biotech Pet Tumor Screening Service Product Offered

    • 11.13.3 PETcision Biotech Pet Tumor Screening Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.13.4 PETcision Biotech Main Business Overview

    • 11.13.5 PETcision Biotech Latest Developments

  • 11.14 Uni-Pharma

    • 11.14.1 Uni-Pharma Company Information

    • 11.14.2 Uni-Pharma Pet Tumor Screening Service Product Offered

    • 11.14.3 Uni-Pharma Pet Tumor Screening Service Revenue, Gross Margin and Market Share (2021-2026)

    • 11.14.4 Uni-Pharma Main Business Overview

    • 11.14.5 Uni-Pharma Latest Developments

• 12 Research Findings and Conclusion